Art. -Nr.: HY-B0203

Nebivolol

(Synonyms: R 065824)

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.94%
CAS. Nr.: 118457-14-0
Formel: C₂₂H₂₅F₂NO₄
Molecular Weight:405.44

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Nebivolol Chemical Structure

CAS. Nr.: 118457-14-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	0.9 μM Compound: 16	Inhibition of mitochondrial respiration in human HCT-116 cells assessed as oxygen consumption rate incubated for 1 hr by Seahorse XF24 extracellular flux analyzer Inhibition of mitochondrial respiration in human HCT-116 cells assessed as oxygen consumption rate incubated for 1 hr by Seahorse XF24 extracellular flux analyzer	[PMID: 36893622]
MDA-MB-231	IC₅₀	2.1 μM Compound: 16	Inhibition of mitochondrial respiration in human MDA-MB-231 cells assessed as oxygen consumption rate incubated for 1 hr by Seahorse XF24 extracellular flux analyzer Inhibition of mitochondrial respiration in human MDA-MB-231 cells assessed as oxygen consumption rate incubated for 1 hr by Seahorse XF24 extracellular flux analyzer	[PMID: 36893622]

In Vitro

Nebivolol improves endothelial dysfunction via its strong stimulatory effects on the activity of the endothelial nitric oxide synthase and via its antioxidative properties^[1].
Nebivolol (0.1 μM-10 μM, 1, 2, 4, 7 or 14 days) inhibits haCSMC or haEC proliferation with IC₅₀ values of ~ 6.0 μM^[2].
Nebivolol (0.1 μM-10 μM, 24 h) induces a moderate rate of apoptosis^[2].
Nebivolol (0.1, 1, 5,10 μM, 4 days)increases NO formation and decreases endothelin-1 secretion in HaCEs^[2]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

haCSMCs (human coronary smooth muscle cells) and haECs (endothelial cells)
Concentration:

0.1 μM-10 μM
Incubation Time:

1, 2, 4, 7 or 14 days
Result:

Reduced proliferation in HaECs and HaCSMCs in a concentration- and time-dependent.

Apoptosis Analysis^[2]

Cell Line:

haCSMCs and haECs
Concentration:

0.1 μM-10 μM
Incubation Time:

24 h
Result:

Induced a moderate apoptosis in concentration-dependent and showed a decrease of haCSMCs in the S-phase by 66%.

Chemical Information

CAS. Nr. 118457-14-0
Appearance Solid
Molecular Weight 405.44
Formel C₂₂H₂₅F₂NO₄
Color White to off-white
SMILES

FC1=CC=C2C(CC[C@]([C@@H](O)CNC[C@H](O)[C@@]3([H])CCC(C=C(F)C=C4)=C4O3)([H])O2)=C1
Synonyms

R 065824
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (6)

All

Sort by:

Journal Impact Factor

Nat Commun

Integrative residue-intuitive machine learning and MD Approach to Unveil Allosteric Site and Mechanism for β2AR. [Abstract]

2024 Sep 16;15(1):8130. PMID: 39285201
Free Radic Biol Med

Targeted delivery of nebivolol via lactoferrin-modified liposomes inhibits NEK7-mediated pyroptosis to ameliorate inflammatory bowel disease. [Abstract]

2026 Aug 16:252:493-508. PMID: 42061481
Br J Pharmacol

Therapeutic potential of small molecules that block receptor-induced Kv7/M-current suppression in neuroprotection, seizures, and pain. [Abstract]

2026 Jul;183(13):3780-3795. PMID: 41956525
PLoS Genet

Nebivolol suppresses glioblastoma progression via dual modulation of mitochondrial metabolism and AKT/mTOR/4EBP1 signaling axis. [Abstract]

2026 Apr 24;22(4):e1012120. PMID: 42030279
J Pharm Biomed Anal

Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]

2021 Feb 20:195:113870. PMID: 33453569
Virology

Structure-based virtual screening of ROCK1 inhibitors for the discovery of Enterovirus-A71 antivirals. [Abstract]

2023 Aug:585:205-214. PMID: 37384967

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (123.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4665 mL

12.3323 mL

24.6646 mL

5 mM

0.4933 mL

2.4665 mL

4.9329 mL

10 mM

0.2466 mL

1.2332 mL

2.4665 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Thomas Münzel, et al. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009 Oct 13;54(16):1491-9. [Content Brief]

[2]. Brehm BR, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001 Feb 1;49(2):430-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4665 mL	12.3323 mL	24.6646 mL	61.6614 mL
	5 mM	0.4933 mL	2.4665 mL	4.9329 mL	12.3323 mL
	10 mM	0.2466 mL	1.2332 mL	2.4665 mL	6.1661 mL
	15 mM	0.1644 mL	0.8222 mL	1.6443 mL	4.1108 mL
	20 mM	0.1233 mL	0.6166 mL	1.2332 mL	3.0831 mL
	25 mM	0.0987 mL	0.4933 mL	0.9866 mL	2.4665 mL
	30 mM	0.0822 mL	0.4111 mL	0.8222 mL	2.0554 mL
	40 mM	0.0617 mL	0.3083 mL	0.6166 mL	1.5415 mL
	50 mM	0.0493 mL	0.2466 mL	0.4933 mL	1.2332 mL
	60 mM	0.0411 mL	0.2055 mL	0.4111 mL	1.0277 mL
	80 mM	0.0308 mL	0.1542 mL	0.3083 mL	0.7708 mL
	100 mM	0.0247 mL	0.1233 mL	0.2466 mL	0.6166 mL

Keywords

Nebivolol

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Nebivolol

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Nebivolol

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Nebivolol

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Nebivolol

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Nebivolol Related Classifications

HY-B0203 Related Classifications